Clinical Trial

A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated October 18, 2024 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-7787 injection monotherapy for patients with advanced solid tumors. To explore the reasonable dosage of SHR-7787 injection monotherapy for patients with advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-19.
Status change: Not Yet Recruiting → Recruiting 2024-10-17
Trial Details
NCT Number NCT06605222
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 201 participants
Start Date 2024-10-04
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-18